INVENTIVA (EPA:IVA) | WebDisclosure

Basculer en Français

9480	Companies
185562	Keywords
117963	Articles
99396	Press releases

Home
Companies
INVENTIVA

PRESS RELEASE

published on 02/10/2025 at 22:00, 9 months 23 days ago

Inventiva reports preliminary 2024 fiscal year financial results¹ and provides a business update
Inventiva reports preliminary 2024 fiscal year financial results and business update, with €9.2 million revenues and €96.6 million cash as of December 31, 2024. Focused on lanifibranor development

Revenues Financial Results 2024 Fiscal Year Inventiva Lanifibranor
BRIEF

published on 01/24/2025 at 22:05, 10 months 12 days ago

Bilan semestriel du contrat de liquidité d'Inventiva avec Kepler Cheuvreux

Contrat De Liquidité Kepler Cheuvreux Biopharmaceutique Transactions Boursières Inventiva
BRIEF

published on 01/24/2025 at 22:05, 10 months 12 days ago

Half-yearly report on Inventiva's liquidity contract with Kepler Cheuvreux

Liquidity Contract Kepler Cheuvreux Biopharmaceutical Stock Market Transactions Inventiva
PRESS RELEASE

published on 01/24/2025 at 22:00, 10 months 12 days ago

Bilan semestriel du contrat de liquidité de la société Inventiva conclu avec Kepler Cheuvreux
Inventiva publie son bilan semestriel du contrat de liquidité avec Kepler Cheuvreux. Espèces de 349 630,55 € et 113 452 actions Inventiva au 31/12/2024. Analyse des transactions du semestre. Entreprise biopharmaceutique axée sur la stéatohépatite et autres maladies

Contrat De Liquidité Bilan Semestriel Kepler Cheuvreux Biopharmaceutique Inventiva
PRESS RELEASE

published on 01/24/2025 at 22:00, 10 months 12 days ago

Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux
Inventiva announces half-year liquidity contract review with Kepler Cheuvreux. Cash and shares available in the liquidity account disclosed. Company focuses on developing oral small molecule therapies for MASH and unmet medical needs

Liquidity Contract Kepler Cheuvreux Clinical-Stage Biopharmaceutical Inventiva MASH
BRIEF

published on 01/22/2025 at 22:05, 10 months 14 days ago

Inventiva's LEGEND Trial Results to be Presented at EASL SLD Summit 2025

Lanifibranor Empagliflozin LEGEND Trial MASH Treatment EASL Summit 2025
BRIEF

published on 01/22/2025 at 22:05, 10 months 14 days ago

Les résultats de l'essai LEGEND d'Inventiva seront présentés au sommet EASL SLD 2025

Lanifibranor Empagliflozine Essai De LEGEND Traitement MASH Sommet EASL 2025
PRESS RELEASE

published on 01/22/2025 at 22:00, 10 months 14 days ago

Results of LEGEND evaluating lanifibranor in combination with empagliflozin in MASH selected for oral presentation at the upcoming EASL SLD Summit 2025
Inventiva announces selection of LEGEND trial results evaluating lanifibranor and empagliflozin for oral presentation at EASL SLD Summit 2025, showing positive outcomes in MASH patients with T2D

Inventiva MASH Lanifibranor Empagliflozin LEGEND Trial
PRESS RELEASE

published on 01/22/2025 at 22:00, 10 months 14 days ago

Résultats de LEGEND évaluant la combinaison de lanifibranor avec empagliflozine dans la MASH ont été sélectionnés pour présentation orale au EASL SLD Summit 2025
Les résultats de LEGEND sur la combinaison de lanifibranor avec empagliflozine pour la MASH seront présentés au EASL SLD Summit 2025. Améliorations métaboliques et sécurité démontrées

MASH Lanifibranor Empagliflozine LEGEND EASL SLD Summit
BRIEF

published on 12/17/2024 at 22:05, 11 months 19 days ago

Inventiva présente à la J.P. Morgan Healthcare Conference

Investisseurs Inventiva NASH Lanifibranor J.P. Morgan Healthcare

Accesswire

Published on 12/05/2025 at 23:30, 36 minutes ago

55 North Mining Inc. Announces Completion of Third and Final Tranche of Private Placement for a Total of $4,202,000
Published on 12/05/2025 at 22:50, 1 hour 16 minutes ago

Banyan Gold Grants Incentive Stock Options
Published on 12/05/2025 at 21:45, 2 hours 21 minutes ago

When the Architecture Becomes Visible: The SMX Revaluation Explained
Published on 12/05/2025 at 21:30, 2 hours 36 minutes ago

The Identity Layer Beneath Everything: Why Markets Are Revaluing SMX All at Once
Published on 12/05/2025 at 21:20, 2 hours 46 minutes ago

Medicus Pharma Ltd. Enters Into $5.1 Million Warrant Inducement

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 22:15, 1 hour 50 minutes ago

CPI PROPERTY GROUP - Changes in Shareholding and Board of Directors
Published on 12/05/2025 at 22:12, 1 hour 53 minutes ago

EQS-Adhoc: CPI PROPERTY GROUP - Change to Distribution Policy
Published on 12/05/2025 at 18:58, 5 hours 7 minutes ago

EQS-Adhoc: HORNBACH Holding AG & Co. KGaA: Reduced earnings in Q3 2025/26 – Guidance for adjusted EBIT at previous year’s level still valid
Published on 12/05/2025 at 18:26, 5 hours 39 minutes ago

POS-Transaction in Own Shares
Published on 12/05/2025 at 18:15, 5 hours 50 minutes ago

Completion of merger to form Helvetia Baloise Holding Ltd

Les Echos

Published on 12/05/2025 at 23:00, 1 hour 6 minutes ago

ALTAREIT : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 12/05/2025 at 23:00, 1 hour 6 minutes ago

ALTAREA : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 12/05/2025 at 23:00, 1 hour 6 minutes ago

ALTAREA : DÉCLARATION MENSUELLE DES OPÉRATIONS RÉALISÉES PAR LA SOCIÉTÉ SUR SES PROPRES TITRES NOVEMBRE 2025
Published on 12/05/2025 at 23:00, 1 hour 6 minutes ago

ALTAREIT : DÉCLARATION MENSUELLE DES OPÉRATIONS RÉALISÉES PAR LA SOCIÉTÉ SUR SES PROPRES TITRES NOVEMBRE 2025
Published on 12/05/2025 at 17:18, 6 hours 48 minutes ago

La vidéo de la réunion de présentation des résultats 2024-2025 du 5 décembre 2025 est disponible

View all LES ECHOS COMFI WIRE